Key Takeaways
- Johnson & Johnson’s MedTech segment, the business OTTAVA sits inside, grew from $7.89 billion to $8.93 billion over two years, but growth decelerated to 4.57% year over year in the June 2026 quarter, the same quarter the robot won FDA approval, down from above 7% in the prior two quarters.
- OTTAVA, JNJ’s newly FDA approved soft tissue surgical robot, received De Novo authorization in August 2026, but management has said on three separate investor calls since then that it will not be a material financial contributor until well into the next decade.
- Street price targets for JNJ have tracked the stock’s rally in a tight band for over a year, and the modest bump after OTTAVA’s approval, from 101.1% to 103.2% of price, looks like incremental optimism rather than a re-rating around the robot.
Johnson & Johnson’s MedTech Segment Was Cooling the Moment OTTAVA Arrived
Two weeks before a string of fireside chats at healthcare conferences in September, Hani Abouhalka stood in a ballroom in Miami at the Society of Robotic Surgery and watched surgeons line up to drive Johnson & Johnson’s newest machine. He later called it the proudest moment of his career. By the time he told that story to a room of analysts on September 9, OTTAVA had become the thing every JNJ conversation circled back to: three conferences in three weeks, a dedicated investor call in early August, and a chairman promising it would be a meaningful contributor to MedTech growth by the end of the decade.
What gets lost in that enthusiasm is the shape of the segment OTTAVA is supposed to reinvigorate.
MedTech operating revenue grew from $7.89 billion in the September 2024 quarter to $8.43 billion a year later, up 6.84%, then to $8.80 billion by December 2025, up 7.45%, and $8.64 billion in March 2026, up 7.73%. That momentum broke in the June 2026 quarter, when MedTech revenue reached $8.93 billion but growth slowed to 4.57% year over year, the exact three month window in which OTTAVA received its FDA approval. Management named specific, temporary causes on the July earnings call: an Abiomed slowdown tied to a UK clinical trial that made physicians more selective with heart pump patients, and roughly 400 basis points of inventory drag in Chinese electrophysiology sales. Neither had anything to do with OTTAVA, which had not shipped a single unit yet.
The rest of the company covered for that slowdown. Innovative Medicine grew from $15.20 billion to $16.38 billion over the same year, up 7.76%, carried by ICOTYDE’s launch outpacing its own internal projections, TREMFYA crossing $2 billion in quarterly sales behind 71% growth in inflammatory bowel disease, and DARZALEX still growing near 18% in a multiple myeloma franchise management now describes as approaching a functional cure. Tim Schmid was direct about what that means for OTTAVA’s timeline, telling the Wells Fargo conference the robot will not have a material financial contribution for the balance of this decade relative to the scope of Johnson & Johnson.
The Real Test for JNJ Stock Isn’t OTTAVA, It’s December 8
The Street’s reaction backs up the read that this is being priced as a long dated option rather than an immediate catalyst.
Analyst price targets have shadowed JNJ’s stock in a narrow band since mid 2025, running between 100% and 103% of the closing price at every checkpoint TIKR tracks. The mean target moved from $257.50 to $277.91 between the June and September readings, a period spanning both the July earnings beat and the August OTTAVA approval, and the target to price ratio only crept up to 103.2%, its highest point in the series but hardly a re-rating. Buy ratings rose from 10 to 11 and one new sell rating appeared. That is the profile of analysts nudging numbers up on a strong quarter, not repricing the stock around a robot management itself says will not matter financially for years.
The more useful date on the calendar is December 8, when JNJ hosts its next Enterprise Business Review, the same forum where the company laid out its current 5% to 7% growth framework back in 2023. Joaquin Duato and Joe Wolk have both said the event will give more granularity on how the business reaches double digit growth by the end of the decade, and John Reed has already flagged 12 molecules in derisked Phase III trials behind DARZALEX.
OTTAVA will presumably be part of that conversation, but based on everything management has said so far, it reads as a 2031 and beyond story arriving just as MedTech’s own growth needs help sooner than that. The risk worth watching is not whether OTTAVA disappoints. It is whether Abiomed and electrophysiology stay soft through 2027, since the robot management is counting on will not be ready to pick up that slack.
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up JNJ stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JNJ stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
